Literature DB >> 15742356

Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma.

Eric T Shinohara1, Adriana Gonzalez, Pierre P Massion, Heidi Chen, Ming Li, Andrea S Freyer, Sandra J Olson, Jeremiah J Andersen, Yu Shyr, David P Carbone, David H Johnson, Dennis E Hallahan, Bo Lu.   

Abstract

BACKGROUND: Survivin, which is a member of the inhibitor of apoptosis protein gene family, regulates both programmed cell death and mitosis. It has been shown that survivin expression and its subcellular localization both have prognostic value for patients with malignant disease. In this study, the authors investigated whether nuclear or cytoplasmic staining of survivin was a prognostic marker for patients with lung carcinoma.
METHODS: Paraffin-embedded tissue blocks from 144 patients with Stage I and II resected nonsmall cell lung carcinoma (NSCLC) were obtained for immunohistochemical staining. Three specimens from each patient were prepared and stained with a survivin-specific antibody. Nuclear and cytoplasmic staining was graded from 1 to 3 based on intensity.
RESULTS: Patients who had nuclear staining for survivin had a significantly increased risk of disease recurrence (hazard ratio, 2.95; P = 0.0046) and death (hazard ratio, 2.74; P = 0.0086).
CONCLUSIONS: The nuclear presence of survivin may be an independent biomarker for disease recurrence and overall survival in patients with resected Stage I and II NSCLC. (c) 2005 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15742356     DOI: 10.1002/cncr.20951

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  30 in total

1.  Down-regulation of survivin expression by small interfering RNA induces pancreatic cancer cell apoptosis and enhances its radiosensitivity.

Authors:  Hai-Tao Guan; Xing-Huan Xue; Zhi-Jun Dai; Xi-Jing Wang; Ang Li; Zhao-Yin Qin
Journal:  World J Gastroenterol       Date:  2006-05-14       Impact factor: 5.742

2.  Survivin gene-expression and splicing isoforms in oral squamous cell carcinoma.

Authors:  Salvatore De Maria; Giuseppe Pannone; Pantaleo Bufo; Angela Santoro; Rosario Serpico; Salvatore Metafora; Corrado Rubini; Daniela Pasquali; Silvana M Papagerakis; Stefania Staibano; Gaetano De Rosa; Ernesto Farina; Monica Emanuelli; Andrea Santarelli; Maria Ada Mariggiò; Lucio Lo Russo; Lorenzo Lo Muzio
Journal:  J Cancer Res Clin Oncol       Date:  2008-07-19       Impact factor: 4.553

3.  Nuclear survivin expression predicts poorer prognosis in glioblastoma.

Authors:  Katsuyuki Shirai; Yoshiyuki Suzuki; Kuniyuki Oka; Shin-ei Noda; Hiroyuki Katoh; Yoshihiko Suzuki; Jun Itoh; Hideaki Itoh; Shogo Ishiuchi; Hideyuki Sakurai; Masatoshi Hasegawa; Takashi Nakano
Journal:  J Neurooncol       Date:  2008-10-25       Impact factor: 4.130

4.  Survivin expression in pre-invasive lesions and non-small cell lung carcinoma.

Authors:  Nalan Akyürek; Leyla Memiş; Ozgür Ekinci; Nurdan Köktürk; Can Oztürk
Journal:  Virchows Arch       Date:  2006-06-30       Impact factor: 4.064

Review 5.  Survivin as a novel target protein for reducing the proliferation of cancer cells.

Authors:  Dongyu Li; Chenghao Hu; Huibin Li
Journal:  Biomed Rep       Date:  2018-03-13

6.  Association of cigarette smoking with the expression of nuclear survivin in pathological Stage IA lung adenocarcinomas.

Authors:  Hiroshi Hirano; Hajime Maeda; Yukiyasu Takeuchi; Yoshiyuki Susaki; Ryoji Kobayashi; Akio Hayashi; Naoko Ose; Yukie Nakazawa; Toshihiko Yamaguchi; Soichiro Yokota; Masahide Mori
Journal:  Med Mol Morphol       Date:  2013-11-09       Impact factor: 2.309

7.  Expression of survivin and patients survival in non-small cell lung cancer: a meta-analysis of the published studies.

Authors:  Li-Nian Huang; Dong-Sheng Wang; Yu-Qing Chen; Cheng-Ling Zhao; Bei-Lei Gong; An-Bang Jiang; Wei Jia; Feng-Dan Hu
Journal:  Mol Biol Rep       Date:  2012-10-13       Impact factor: 2.316

8.  Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma.

Authors:  Junichi Okamoto; Iwao Mikami; Yuichi Tominaga; Kristopher M Kuchenbecker; Yu-Ching Lin; Dawn T Bravo; Genevieve Clement; Adam Yagui-Beltran; M Roshni Ray; Kiyoshi Koizumi; Biao He; David M Jablons
Journal:  J Thorac Oncol       Date:  2008-10       Impact factor: 15.609

9.  Prognostic significance of nuclear survivin expression in resected adenoid cystic carcinoma of the head and neck.

Authors:  Yoon Ho Ko; Sang-Young Roh; Hye Sung Won; Eun Kyoung Jeon; Sook Hee Hong; Myung Ah Lee; Jin Hyoung Kang; Young Seon Hong; Min Sik Kim; Chan-Kwon Jung
Journal:  Head Neck Oncol       Date:  2010-10-30

10.  Anticancer Potentials of Root Extract of Polygala senega and Its PLGA Nanoparticles-Encapsulated Form.

Authors:  Saili Paul; Soumya Sundar Bhattacharyya; Naoual Boujedaini; Anisur Rahman Khuda-Bukhsh
Journal:  Evid Based Complement Alternat Med       Date:  2010-09-21       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.